

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

## FORM 1: APPLICANT GENERAL INFORMATION

Applicant Information				
Applicant Name				
Connaissance Software LLC				
Mailing Address				
9716 Wild Oak Dr.				
City	Apt/Ste #	State	ZIP Code	Country
Windermere		FL	34786	USA

Contact Information		
First Name	Last Name	Middle Initial
Bruce	Knox	R
Telephone Number	Designated Email (for Department/Applicant Communications)	
407-948-9618	bruce@knoxhort.com	

Medical Director Information		
First Name	Last Name	Middle Initial
Orlando	Florete Jr.	G
Florida Physician (MD or DO) License Number	Telephone Number	Email
ME0058430	904-233-5055	oflorete@gmail.com

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

# REDACTED COPY

The Applicant has redacted sections of the following application containing trade secrets under Section 119.0715, F.S. – A trade secret, as defined in s. 688.002, that is held by an agency is confidential and exempt.

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

# *State of Florida*

## *Department of State*

I certify from the records of this office that CONNAISSANCE SOFTWARE, LLC is a limited liability company organized under the laws of the State of Florida, filed on February 20, 2018, effective February 20, 2018.

The document number of this limited liability company is L18000045670.

I further certify that said limited liability company has paid all fees due this office through December 31, 2023, that its most recent annual report was filed on March 13, 2023, and that its status is active.

*Given under my hand and the  
Great Seal of the State of Florida  
at Tallahassee, the Capital, this  
the Thirteenth day of March, 2023*



  
*Secretary of State*

Tracking Number: 8414147243CC

To authenticate this certificate, visit the following site, enter this number, and then follow the instructions displayed.

<https://services.sunbiz.org/Filings/CertificateOfStatus/CertificateAuthentication>

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**



**CERTIFICATE OF NURSERY REGISTRATION**

Section 581.131, F.S. and Rule 5B-2.002, F.A.C  
1911 S.W. 34th St. P.O. Box 147100, Gainesville, FL 32614-7100 (352) 395-4700

**WILTON SIMPSON**  
**COMMISSIONER**

**ISSUED TO:**

**CONNAISSANCE SOFTWARE LLC**  
**KNOX, BRUCE**  
**9716 WILD OAK DR**  
**WINDERMERE, FL 34786-8335**

**THIS CERTIFICATE EXPIRES: 04/21/2024**

**FEE PAID: \$35.00**

**REGISTRATION NO.: 48030943**

**DATE ISSUED: 04/21/2023**

THIS IS TO CERTIFY that the nursery stock on the premises of the nursery shown hereon has been inspected for plant pests and meets at least the minimum requirements of Section 581.131, Florida Statutes.

THIS CERTIFICATE OF REGISTRATION MUST BE DISPLAYED or in the immediate possession of any person engaged in the sale or distribution of nursery stock.



**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**




**FORM 2: WAIVER AGREEMENT AND STATEMENT  
For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.

I understand that the OMMU may disclose to the applicant for Medical Marijuana Treatment Center (MMTC) licensure listed below whether I am authorized to serve as an owner or manager for the MMTC upon licensure, as provided in section 381.986, F.S., Florida Administrative Code Chapter 64-1, and applicable






**FORM 2: WAIVER AGREEMENT AND STATEMENT**  
**For Criminal History Record Checks**


I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.

I understand that the OMMU may disclose to the applicant for Medical Marijuana Treatment Center (MMTC) licensure listed below whether I am authorized to serve as an owner or manager for the MMTC upon licensure, as provided in section 281.086, F.S., Florida Administrative Code.








**FORM 2: WAIVER AGREEMENT AND STATEMENT  
For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.


I understand that the OMMU may disclose to the applicant for Medical Marijuana Treatment Center (MMTC) licensure listed below whether I am authorized to serve as an owner or manager



## **FORM 2: WAIVER AGREEMENT AND STATEMENT For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.



**FORM 2: WAIVER AGREEMENT AND STATEMENT  
For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.


[REDACTED]

## **FORM 2: WAIVER AGREEMENT AND STATEMENT For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.

I understand that the OMMU may disclose to the applicant for Medical Marijuana Treatment Center (MMTC) licensure listed below whether I am authorized to serve as an owner or manager for the MMTC upon licensure, as provided in section 381.986, F.S., Florida Administrative Code







## **FORM 2: WAIVER AGREEMENT AND STATEMENT For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.

I understand that the OMMU may disclose to the applicant for Medical Marijuana Treatment Center (MMTC) licensure listed below whether I am authorized to serve as an owner or manager







**FORM 2: WAIVER AGREEMENT AND STATEMENT  
For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.







**FORM 2: WAIVER AGREEMENT AND STATEMENT  
For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.






**FORM 2: WAIVER AGREEMENT AND STATEMENT  
For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained in any such report. I am aware that procedures for obtaining a change, correction, or updating of the FDLE or FBI criminal history are set forth in section 943.056, F.S., and Title 28, CFR, section 16.34.

I understand that the OMMU may disclose to the applicant for Medical Marijuana Treatment Center (MMTC) license listed below, the information that



**FORM 2: WAIVER AGREEMENT AND STATEMENT**  
**For Criminal History Record Checks**

I hereby authorize the Livescan Service Provider of my choosing to submit a set of my fingerprints to the Florida Department of Law Enforcement (FDLE) for the purpose of accessing and reviewing Florida and national criminal history records that may pertain to me. I understand that my background report will be sent to the Florida Department of Health, Office of Medical Marijuana Use (OMMU), and that I would be able to receive any national criminal history record that may pertain to me directly from the Federal Bureau of Investigation (FBI) pursuant to Title 28, Code of Federal Regulations (CFR), sections 16.30-16.34, and that I could then freely disclose any such information to whomever I choose.

I understand that my fingerprints may be retained at FDLE and the FBI for the purpose of providing any subsequent arrest notifications to the OMMU. I further understand that, upon request, the FDLE may provide me a copy of the criminal history record report, if any, it receives concerning me and that I am entitled to challenge the accuracy and completeness of any information contained



**REDACTED COPY**



**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

























**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.4.3 – Ability to Secure Cultivation Infrastructure**

















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**























**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.5.3 – Ability to Secure Processing Infrastructure**













**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**























**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.6.2 Addendum**















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.6.3 – Ability to Secure Dispensing Infrastructure**













**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.7.1 Addendum**





















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**









**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.7.4 – Personnel Screening and Training**











**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**







**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.8.1 – Experience in the Marijuana Industry (Applicant)**













**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.8.2 – Other Relevant Experience**













**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**













**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**









**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.9.1 – Experience in the Marijuana Industry (Medical Director)**











**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.9.2 – Other Relevant Experience**





**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.9.2 Addendum**

# REDACTED COPY

## CURRICULUM VITAE

**NAME:** Orlando G. Florete, Jr., M.D.

**HOME PHONE #:** 904.233.5055

**WORK ADDRESS:** 4131 University Blvd. South Bldg. 12  
Jacksonville, Florida 32216

**E-MAIL ADDRESS:** [oflorete@gmail.com](mailto:oflorete@gmail.com)

**PRESENT POSITION:** Medical Director  
Orles Pain Management and Regenerative Medicine Group, PA

Medical Director  
Aries Pain Procedures, Inc

Chief Medical Officer  
International Stem Cell Medical Center

President  
FSIPP Research & Educational Foundation

Immediate Past President  
Florida Society of Interventional Pain Physicians

President-Founder  
American Society of Regenerative Medicine

Director at Large  
American Society of Pain & Neuroscience

Director at Large, Specialty Section  
Florida Medical Association

Consultant  
APEX Biologics, Park City, Utah

Consultant, Expert Medical Advisor  
Florida Department of Health  
Prosecution Services Unit  
Tallahassee, Florida 32399-3265

Consultant  
Jacksonville Surgery Center  
8071 A.C. Skinner Parkway  
Jacksonville, Florida 32216

**PAST POSITIONS:** 2017-2018  
Co-Founder  
American Medical Marijuana Physicians Association



# REDACTED COPY

2012-2020

Member, Executive Board

Florida Society Interventional Pain Physicians

2016-2018

Medical Director

Knox Medical, Winter Garden, Florida

2016-2018

Medical Director

The Green Solutions, Gainesville, Florida

2012-2014

Consultant

Prescription Drug Monitoring Program

Florida Department of Health

Tallahassee, Florida 32399-3265

2000-2016

Expert Medical Advisor

Florida Department of Labor and Employment Security

Division of Worker's Compensation

2000-2018

Medical Director, Institute of Pain Management

2009-2018

Medical Director, Florida Institute of Medical Research

2001 - 2009

Chief, Pain Management Services

Baptist Medical Center

2001-2009

Member, Baptist Medical Center Board

1996 – 1998

Consultant

Medical Partners Surgery Center

Pain Management Service

1994 – 1998

Clinical Assistant Professor

Departments of Anesthesiology and Medicine

University of Florida College of Medicine

1994-2000

Pain Management Consultant

The Northeast Florida Pain Center

University of Florida Health Science Center/Jacksonville

1994-1997

Attending Anesthesiologist

University Medical Center

Jacksonville, Florida

# REDACTED COPY

1994-1997  
Attending Physician  
Department of Medicine/Critical Care Medicine  
University Medical Center, Jacksonville, Florida

1994-1997  
Director  
Acute Pain Service  
University Medicine Center  
Jacksonville, Florida

1994-1997  
Co-Director  
Post-Anesthesia Care Unit  
Department of Anesthesiology  
University Medical Center Jacksonville, Florida

## APPOINTMENTS:

Research Committee  
American Academy of Pain Medicine  
2008 - 2012

Liason  
Committee on External Affairs  
American Academy of Pain Medicine  
2007 – 2012

Website Development Committee  
Duval County Medical Society  
1999 – 2003

Faculty  
National Initiative in Continuing Medical Education  
Institute for Continuing Healthcare Education  
210 West Washington Square, 8<sup>th</sup> Floor  
Philadelphia, PA 19106  
1999 – Present

Speakers Bureau, Pfizer, Inc.  
235 East 42<sup>nd</sup> Street  
New York, NY 10017  
1998 – Present

Speakers Bureau, Xanodyne Pharmaceuticals  
One Riverfront Pl  
Newport, KY 41071  
2010 - Present

Speakers Bureau, NeurogesX, Inc.  
2215 Bridgepointe Parkway, Suite 200  
San Mateo, California 94404  
2010 – Present

# REDACTED COPY

Speakers Bureau, Lilly USA, LLC  
150 Meadowlands Parkway  
Secaucus, NJ 07094-2304  
2004 – Present

Speakers Bureau, Forest Laboratories, Inc.  
IntraMed Educational Group  
230 Park Avenue South, 5<sup>th</sup> Floor  
New York, NY 10003  
2010 - Present

Speakers Bureau, Janssen Pharmaceuticals, Inc.  
20 Avenue at the Common  
Shrewsbury, NJ 07702  
1997 – Present

Prialt Medical Advisory Board  
Azur Pharma, Inc.  
1818 Market Street, Suite 2350  
Philadelphia, PA  
2011 - Present

Committee on Pain Management  
Florida Society of Anesthesiologists  
1997 – 2003

Committee on Job Placement  
Florida Society of Anesthesiologists  
1997 – 2003

Legislative Committee  
Duval County Medical Society  
1996 – 2004

Committee on Journal and Communications  
Duval County Medical Society  
1996 – 2005

Faculty, Current Health Focus Program  
Health Education Technologies  
Health and Medical Communications, Inc.  
220 East 42<sup>nd</sup> Street  
New York, New York 10017  
1996 – Present

Associate Editor  
Jacksonville Medicine  
1995 – 2002

Faculty, Anesthesiology and Pain Board Review  
Osler Institute  
1995 – 2004

# REDACTED COPY

Member, Intensive Care Unit Committee  
University Medical Center  
Jacksonville, Florida  
1996 – 1997

Member, Cancer Executive Committee  
University Medical Center  
Jacksonville, Florida  
1996 – 1997

Member, Committee on Education and Annual  
Scientific Meeting  
Subcommittee on Technical Exhibits  
Society for Airway Management - 1996

Director, Research Division  
Department of Anesthesiology  
University of Florida Health Science Center/Jacksonville  
1995 – 1997

Coordinator, Residents' Training and Education  
Department of Anesthesiology  
University of Florida Health Science Center/Jacksonville  
1995 – 1997

Director, Continuing Medical Education  
Department of Anesthesiology  
University of Florida Health Science Center/Jacksonville  
1994 – 1996

## LICENSURE AND CERTIFICATIONS:

2000-2022  
Diplomate, American Board of Pain Medicine

1998  
Diplomate, American Academy of Pain Management

1994  
Diplomate, American Board of Anesthesiology

1993  
Kentucky Physician's License # 29882

1990  
Federal Licensure Examination (FLEX)2000

Florida Physician's License #ME 0058430

1983  
Visa Qualifying Examination (VQE)

1982  
ECFMG

# REDACTED COPY

1982  
Philippine Physician's Licensure

## EDUCATIONAL BACKGROUND:

1981  
Doctor of Medicine (cum laude)  
Cebu Institute of Medicine, Cebu City, Philippines

1977  
Bachelor of Science in Medical Technology (cum laude)  
Velez College, Cebu City, Philippines

## POSTGRADUATE TRAINING:

July 1, 1989 – June 30, 1993  
Residency, Anesthesiology  
University of Florida College of Medicine

1993  
Pain Management Training  
Department of Anesthesiology  
University of Kentucky (April – May 1993)  
University of Virginia (June, 1993)

1987 – 1989  
Fellow, Critical Care Medicine  
Department of Anesthesiology  
University of Florida College of Medicine

1985 – 1986  
Fellow, Cardiology  
University of the Philippines College of Medicine

1983 – 1985  
Residency, Internal Medicine  
University of the Philippines College of Medicine

1981- 1982  
Postgraduate Internship  
University of the Philippines College of Medicine

## CLINICAL RESEARCH TRIALS:

2003  
Pharmacia Pharmaceuticals, Inc.  
Drug: Bextra  
Treatment of Post Surgical Pain from Laparoscopic  
Cholecystectomy Surgery

2003  
Janssen Pharmaceuticals, Products, L.P.  
Drug: Duragesic7 (Fentanyl Transdermal System)  
Functionally Changes Associated with Patients  
Transitioning from Chronic Use of Short-Acting Opioids to  
Duragesic7 for Management of Chronic Low Back pain

# REDACTED COPY

2003

Novartis Pharmaceuticals, Inc.

Drug: Trileptal

Patients with Neuropathic Pain due to Radiculopathy

2004

GlaxoSmithKlein Pharmaceuticals, Inc.

Drug: Lamotrigine Tablets

Subject with Neuropathic Pain and Inadequate Pain Relief  
with Gabapentin, Tricyclic Antidepressants or Non-Narcotic  
Analgesics

2004

Ligand Pharmaceuticals, Inc.

Drug: Avinza<sup>7</sup>

Pain Control and Improved Functioning in Patients  
with Chronic Pain Treated with Avinza<sup>7</sup>

2004

Ortho Mc Neil Pharmaceuticals, Inc.

Drug: Tramadol HCl/Acetaminophen

Evaluate the Efficacy and Safety in the Treatment of  
Patients with Painful diabetic Neuropathy

2004

MEDTAP International

Focus Group

To Identify Relevant Domains for the Assessment of  
Patient-Reporting Outcomes in Chronic Pain

2004

Harris Intractive, Inc.

Managed by Edgar Adams, PhD.

Pain Control and Improved Functioning in  
Patients with Chronic Pain Treated with Avinza

2004

Elan Pharmaceuticals, Inc.

Drug: Intrathecal Zincontide (PRIALTJ)

Intrathecal Effectiveness and Safety Trial in Patients  
with Chronic Severe Pain

2005

Cephalon, Inc.

Drug: OraVescent<sup>7</sup> Fentanyl Citrate

Treatment of Breakthrough Pain in Opioid-Tolerant  
Cancer Patients

2005

Cephalon, Inc.

Drug: OraVescent<sup>7</sup> Fentanyl Citrate

A Double-Blind, Randomized, Placebo-Controlled Study to  
Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate  
for the Management of Breakthrough Pain in Opioid-Tolerant  
Patients With Chronic Pain Neuropathic Pain.

# REDACTED COPY

2005

Cephalon, Inc.

Drug: OraVescent<sup>7</sup> Fentanyl Citrate

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Low Back Pain.

2005

Cephalon, Inc.

Drug: OraVescent<sup>7</sup> Fentanyl Citrate

A Open-Label, 12-Month Study to Evaluate the Safety, Tolerability, and Efficacy of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Non-Cancer Pain.

2005

Neurogesx, Inc.

Drug: Transdermal Capsaicin Patches

A Randomized, Double-Blind, Controlled Study of Transdermal Capsaicin Patches for the Treatment of Postherpetic Neuralgia.

2005

Cephalon, Inc.

Drug: OraVescent<sup>7</sup> Fentanyl Citrate

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of OraVescent<sup>7</sup> Fentanyl Citrate in Opioid-Tolerant patients With Cancer and Breakthrough Pain

2005

ZARS. Inc.

Drug: CHADD

A Double-Blind, Placebo-Controlled, Multiple Crossover Proof-of-Concept Study to Evaluate the Efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) Applied over a ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Breakthrough Pain in patients with Moderate to Severe Non-Malignant Chronic Pain

2005

BioDelivery Sciences International, Inc.

Drug: BEMA Fentanyl

A Double-Blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects.

2005

BioDelivery Sciences, Inc.

Drug: BEMA Fentanyl

An Open-Label, Long-Term Treatment Evaluation of the Safety of BEMA Fentanyl use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

# REDACTED COPY

2005

ENDO Pharmaceuticals, Inc.

Drug: Fentanyl Citrate Sublingual Tablets

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients Followed by up to 12-Month Non-Randomized, Open-Label Extension to Assess Long-Term Safety.

2005

UCB Pharma, Inc.

Drug: Levetiracetam

A Clinical Grant-In-Aid Pilot Program for a Single Center, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients with Complex Regional Syndrome Type I (CRPS I)

2005

Ligand, Inc.

Clinical Grant-In-Aid Pilot Program for a Single-Center Open-Label Study to Evaluate Safety and Efficacy of Avinza in the Management of Lumbar Radicular Pain

2006

Jazz Pharmaceuticals, Inc.

Drug: Xyrem

A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Subjects with Fibromyalgia

2006

Jazz Pharmaceuticals, Inc.

Drug: Xyrem

A Long-Term, Open-Label and Efficacy Study of Xyrem in Adults with Fibromyalgia

2006

PAR Pharmaceuticals, Inc.

Drug: Megestrol Acetate Concentrated Suspension

A Randomized, Double-Blind, Placebo-Controlled Study of Megestrol Acetate Concentrated Suspension (MA-CS) for the Treatment of Cancer-Associated Anorexia in Subjects with Cancer of Multiple Types

2006

PARS Pharmaceuticals, Inc.

Drug: Megestrol Acetate Concentrated Suspension

A Randomized, Double-Blind, Placebo-Controlled Study of Megestrol Acetate Concentrated Suspension (MA-CS) for the Treatment of Cancer-Associated Anorexia in Subjects with Lung Cancer or Pancreatic Cancer



# REDACTED COPY

2006

Novartis Pharmaceuticals, Inc.

Drug: Tegaserod (HTF919)

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo given Orally for 12 Weeks for the Treatment of Opioid-Induced Constipation (OIC) in Patients with Chronic Non-Cancer pain

2006

Novartis Pharmaceuticals, Inc.

Drug: Tegaserod (HTF919)

A 52-Week Extension to Study to Evaluate the Safety and Efficacy of Tegaserod (6mg b.i.d and 12 mg o.d.) Given Orally for the Treatment of Opioid-Induced Constipation (OIC) in Patients with Chronic Non-Cancer pain

2006

Alpharma Branded Products Division

Drug: Kadian NT

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee

2006

Alpharma Branded Products Division

Drug: Kadian NT

A Long-Term, Open-Label, Safety Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Chronic Moderate to Severe Nonmalignant pain

2006

DEPOMED, Inc.

Drug: Gabapentin Extended Release (G-ER)

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients with Postherpetic Neuroalgia

2006

Advanced Bionics

A Capability of Electrical Measurements to Estimate and Track Relative Spatial Orientation of Spinal Cord Stimulation (SCS) Leads

2007

Sucampo Pharmaceuticals, Inc.

Drug: Lubiprostone

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Bowel Dysfunction

# REDACTED COPY

2007

Sucampo Pharmaceuticals, Inc.

Drug: Lubiprostone

A Multi-Center, Open-Labeled Study of the Long-Term Safety and Efficacy of Lubiprostone in Patients with Opioid-Induced Bowel Dysfunction

2007

Advanced Neuromodulation Systems, Inc

Constant Current vs. Constant Voltage Study

2007

Johnson & Johnson Regenerative Therapeutics

Drug: Intradiscal rhGDF-5

A phase I/II, Multicenter, Placebo-Controlled, Double-Blind, Randomized, Single Administration, Dose Finding, Clinical Trial to Evaluate the Safety and Tolerability for the Treatment Of Early Stage Lumbar Disc Degeneration

2007

Pfizer

Drug: Pregabalin

A Randomized, Double-Blind, Multi-Center Dose-Ranging Study of the Efficacy and Safety of Pregabalin compared to Placebo in The Adjunctive Treatment of Post-Surgical pain after Primary Inguinal Hernia Repair

2007

Neuromed Pharmaceuticals, Inc.

Drug: OROS Hydromorphone HCl (NMED-1077)

A Phase III, Flexible-Dose Titration Followed by a Randomized Double-Blind Study of controlled-Release OROD Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients with Osteoarthritis Pain

2007

Neuromed Pharmaceuticals, Inc.

Drug: OROD Hydromorphone HCl (NMED-1077)

A Open-Label, 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of ORVAESCENT Fentanyl Citrate For the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Non-Cancer Pain

2007

Florida Institute of Medical Research

Drug: Levetiracetam

Clinical Grant-In-Aid Pilot Program For A single Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to evaluate the Safety and Efficacy of Levetiracetam in Patients with Complex Regional Pain Syndrome Type 1(CRPS1)

# REDACTED COPY

2007

ENDO Pharmaceuticals, Inc.

Drug: Fentanyl Citrate Sublingual Tablets

A Double-Blind Randomized, Placebo-Controlled,  
Multi-Center Study to Evaluate the Efficacy and Safety for the  
Treatment of Breakthrough Pain in Opioid Tolerant Cancer  
Patients Followed by an up to 12 month Non-Randomized,  
Open-label Extension to Assess Long-Term Safety

2008

Pfizer

Drug: Tramadol Hydrochloride

A Six Week Double-Blind, Randomized, Multi-Center  
Comparison Study of the Analgesic Effectiveness of  
Celecoxib Compared to Tramadol Hydrochloride in  
Subjects with Chronic Low Back Pain

2008

ENDO Pharmaceutical, Inc.

Drug: Sufentanil Transdermal

An Open-Label, Two-Stage, Phase II Study to Explore the  
Titration Schedule for Transitioning Opioid-Experienced  
Patients with Non-Malignant Moderate to Severe Chronic  
Pain for Current Opioid Therapy to the Sufentanil  
Transdermal Therapeutic System

2008

Boston Scientific

Capability of Electrical Measurements to Estimate and Track  
Relative Spatial Orientation of Spinal Cord Stimulation (SCS)  
Leads

2008

Ortho-McNeil Janssen Scientific Affairs, LLC

Drug: Oxycodone Immediate Release

“ A Prospective, Multi-Center, Observational Registry of  
Patients Using Prescription Medications Containing Oxycodone  
Immediate Release for the Treatment of pain

2008

Advanced Neuromodulation Systems, Inc.

A Prospective, Multi-Centered Clinical Evaluation of the EON™  
16-Channel Implantable Pulse Generator (IPG) in Combination  
With Paddle Lead(s) for the Management of Chronic Back Pain  
With or Without Leg Pain

2008

Eli Lilly and Company

An Open-Label, Randomized Study Comparing Duloxetine,  
Pregabalin and Duloxetine in combination with Gabapentin  
In Patients with Diabetic Peripheral Neuropathic Pain

# REDACTED COPY

2009

GW Pharmaceuticals

Drug: Sativex

A Double-Blind, Randomized, Placebo Controlled, Parallel Group Dose-Range Exploration Study of SATIVEX® in Reliving Pain In Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy

2009

Wyeth Research

Drug: MOA-728 Subcutaneous Injection

An Open-Label Study to Evaluate the Long-Term Safety Of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects with Non- Malignant Pain

2009

ENDO Pharmaceuticals, Inc.

Drug: Axomadol

A Phase IIB, Randomized, Double-Blind, Two-Arm, Multi-Center, Placebo-Controlled Study to Assess the Efficacy and Safety of EN3324 (Axomadol) in Subjects With Moderate to Severe Chronic Low Back Pain

2009

ENDO Pharmaceuticals, Inc.

Drug: Oxymorphone Extended Release (ER) Tablets

An Open-Label Safety and Tolerability Study of Immediate-Release and Extended-Release Oxymorphone In Opioid-Tolerant Pediatric Subjects with Chronic Pain

2009

AcelRx, Inc.

Drug: ARX-F02

A Multicenter, Randomized, Placebo-Controlled, Crossover Study for the Evaluation of ARX-F02 Compared to Placebo In the Treatment of Cancer Breakthrough Pain

2009

Grunenthal GmbH, Global Research and Development

Drug: Axomadol

A Randomized, Multi-Center, Double-Blind, Parallel-Group Trial to Assess the Analgesic Efficacy and Safety of a new Diabetic Peripheral Neuropathy

2009

St. Jude Medical Neuromodulation Division

Partnership for Advancement in Neuromodulation (Pain):

A Prospective Clinical Outcomes Registry

# REDACTED COPY

2010

Zogenix

Drug: Hydrocodone Bitartrate Controlled Release  
A Randomized Double-Blind, Placebo-Controlled Trial to  
Evaluate the Efficacy, Tolerability and Safety of Hydrocodone  
Bitartrate Controlled-Release in Opioid-Experienced Subjects  
With Moderate to Severe Chronic Low Back pain

2010

Zogenix

Drug: Hydrocodone Bitartrate Controlled Release  
A Long-Term Open-Label Safety Study of Hydrocodone  
Bitartrate Controlled-Release Capsules with Flexible Dosing to  
Treat Subjects with Moderate to Severe Chronic Pain

2010

Progenics

Drug: MNTX 3201

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-  
controlled, Parallel-group Study of Oral Methylnaltrexone (OM)  
for the Treatment of Opioid-Induced Constipation (OIC) in  
Subjects with Chronic, Non-Malignant Pain

2011

King Pharmaceutical

Drug: Oxycodone Hydrochloride and Naltrexone Hydrochloride  
Extended-Release  
A Multicenter, 12-Month, Open-Label, Single-Arm, Safety  
Study of Oxycodone Hydrochloride and Naltrexone  
Hydrochloride Extended-Release Capsules in Subjects With  
Moderate to Severe Chronic Noncancer Pain

2011

AstraZeneca

Drug: NKTR-118

An Open-Label 52-week Study to Assess the Long-Term Safety  
of NKTR-118 in Opioid-Induced Constipation (OIC) in patients  
with Non-Cancer-Related Pain.

2011

Purdue Pharma

Drug: Oxycodone/Naloxone Controlled Release Tablets  
A Randomized, Double-blind, Placebo-Controlled, Multicenter  
Trial with an Enriched Study Design to Assess the Efficacy and  
Safety of Oxycodone/Naloxone Controlled-Released Tablets (OXN) Compared to  
Placebo in Opioid-Experienced Subjects with Moderate-to-Severe Pain due to  
Chronic Low Back Pain who Require Around-the-Clock Opioid Therapy.

2012

AstraZeneca

Drug: NKTR-118

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and  
Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced  
Constipation (OIC).

# REDACTED COPY

2012

Theravance, Inc.

Drug: TD-1211

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid Induced Constipation.

GW PHARMA LTD, 2012

Drug: Sativex®; Nabiximols

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients with Advanced Cancer, who Experience Inadequate Analgesia during Optimized Chronic Opioid Therapy

2012

ENDO Pharmaceutical

Drug: BEMA® Buprenorphine

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter, Randomized Withdrawal Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of BEMA®

Buprenorphine in Opioid-Experienced Subjects with Moderate-to-Severe Chronic Low Back Pain Requiring Around-the-clock Opioid Analgesia for an Extended Period of Time

2012

ENDO Pharmaceutical

Drug: BEMA® Buprenorphine

A Phase 3, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of BEMA®

Buprenorphine in Opioid-Naïve Subjects with Moderate-to-Severe Chronic Low Back Pain Requiring Around-the-clock Opioid Analgesia for an Extended Period of Time

2012

Purdue Pharma

Drug: Oxycodone / Naloxone Controlled-Release Tablets

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Active-controlled, Parallel-Group, Multicenter Trial of Oxycodone/Naloxone Controlled-Release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-Induced Constipation (Compared to Oxycodone Controlled-Release Tablets (OXY) in Opioid-Experienced Subjects with Uncontrolled Moderate-to-Severe Chronic Low Back Pain and a History of Opioid-Induced Constipation who Require Around-the-Clock Opioid Therapy

2013

GW PHARMA LTD

Drug: Sativex®; Nabiximols

A Multicenter, Non-Comparative, Open-Label Extension Study to Assess the Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients with Uncontrolled Persistent Chronic Cancer Related Pain

2013

Teva Branded Pharmaceuticals

Drug: Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 30 to 90 mg Every 12-Hours for Relief of Moderate-to-Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

# REDACTED COPY

2013

Teva Branded Pharmaceuticals

Drug: Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) A 6-Month, Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate-to-Severe Pain in Patients with Chronic Low Back Pain who Require Opioid Treatment for an Extended Period of Time

2013

Cubist Pharmaceuticals

Drug: CB-5945 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

2013

Cubist Pharmaceuticals

Drug: CB-5945

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

2014

Shionogi, Inc

Drug: Naldemedine

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Naldemedine in the Treatment of Opioid-Induced Constipation in Subjects with Non-Malignant Chronic Pain Receiving Opioid Therapy

## ACHIEVEMENTS, AWARDS, AND SCHOLARSHIPS:

2013

President's Award for Outstanding Achievement  
Florida Society of Interventional Pain Physicians

1993

Community Service Award  
Department of Anesthesiology  
University of Florida College of Medicine

1989

Certificate of Excellence  
Audiovisual Aids Research Paper Presentation  
15<sup>th</sup> Annual Gulf-Atlantic Anesthesia  
Residents' Conference, New Orleans, Louisiana

1985

Golden Stethoscope Award  
Department of Internal Medicine  
University of the Philippines College of Medicine

1982

Most Outstanding Rotating Intern in Medicine  
University of the Philippines College of Medicine

# REDACTED COPY

1981

Cum Laude, Doctor of Medicine

Cebu Institute of Medicine

Class Valedictorian in a Class of 155 Medical Graduates

Philippine Medical Association Most Outstanding Medical  
Graduate Awardee

(Rafael Enrile Award)

1981

Winthrop Stearns Scholarship Award

Excellence in the Study of Anatomy Award

Cebu Institute of Medicine

President Gold Medal Award in Biochemistry and  
Microbiology

1977 – 1980

Full College Scholarship Award

Cebu Institute of Medicine

1977

Cum Laude

Bachelor of Science in Medical Technology

## **AFFILIATIONS:**

Member, International Anesthesia Research Society

Member, American Society of Anesthesiologists

Founding Member, Society of Airway Management

Member, American Pain Society

Member, American Academy of Pain Management

Member, American Academy of Pain Medicine

Member, American Society of Interventional Pain Physicians

Member, American Society of Regional Anesthesiology

Member, Florida Society of Anesthesiologists

Member, PEEP Society

Member, Duval County Medical Society

Member, Florida Medical Association

Member, American Medical Association

Member, Florida Academy of Pain Medicine

Member, Florida Society of Interventional Pain Physicians

Member, Philippine Medical Society of Northeast Florida



# REDACTED COPY

Life Member, Winthrop Stearns Fellows and Scholars Association

## BOOKS: CHAPTERS IN:

1. Wilson, Florete OG Jr, Rowe DS: Interventional pain management. In Cucchiarra R (eds). Neuroanesthesia. 2<sup>nd</sup> edition 1998
2. Florete OG Jr, Kirby RR: Airway Management. Inc Civetta J, Kirby RR, Taylor R (eds). Critical Care. 3<sup>rd</sup> edition. Philadelphia. J.B. Lippincott Co. 1997
3. Melker R, Florete OG Jr: Percutaneous dilational cricothyrotomy and tracheotomy. In Benumoff JL (ed). Airway Management: Principles and Practice. St. Louis. Mosby Year Book, Inc. 1996, PP 484-512
4. Idris AH, Florete OG Jr, Milker RJ, Chandra N: Physiology of ventilation, oxygenation, and carbon dioxide elimination during cardiac arrest. In Paradis NA, Halperin HR, Nowak RM (eds). Cardiac Arrest – The Science and Practice of Resuscitation Medicine. Baltimore. Williams & Wilkins. 1996, PP 382-419
5. Milker RJ, Florete OG Jr: Cricothyrotomy – Review and Debate. In Doyle DJ, Sandler AN (eds). Anesthesiology Clinics of North America. Philadelphia. W.B. Saunders Co. 1995, PP 565-583
6. Florete OG Jr: Airway devices and their application. In Kirby RR, Gravenstein N (eds). Clinical Anesthesia Practice. Philadelphia. J.B. Lippincott Co. 1994 PP 298-319
7. Florete OG Jr: Airway management. In Civetta J, Kirby RR, Taylor R (eds). Critical Care. 2<sup>nd</sup> edition. Philadelphia. J.B. Lippincott Co. 1992, PP 1419-1436
8. Florete OG Jr., Gallagher TJ: Cardiac disease, congestive heart failure, coronary artery disease, and vascular disease. In Cheng E, Kay J (eds): Anesthesia and the Medically Compromised Patient. Philadelphia, LB Lippincott Co. 1990 PP 2-73
9. Florete OG, Jr., Gammage GW: Complications of mechanical ventilatory support. In Kirby RR, Banner MJ, Downs JB (eds): Clinical applications of ventilatory support. New York, Churchill Livingstone, 1990. PP 337-360

## PUBLISHED ABSTRACTS:

1. Lobato EB, Arteaga A, Lewis J, Paige GB, Loudermilk E, Brown MM, Florete OG Jr: Echocardiographic analysis of left ventricular (LV) function after unilateral stellate ganglion blockade (SGB), abstracted. Anesthesiology 87:A68, 1997.
2. Lobato EB, Florete OG Jr, Paige GB: Effect of position, positive intrathoracic pressure, and hepatic compression on internal jugular vein area, abstracted. Can J Anaesth 43:A22A, 1996
3. Lobato EB, Florete OG Jr, Bingham HL: Single dose milrinone and discontinuation of cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction, abstracted. Can J Anaesth 43:A29A, 1996
4. Lobato EB, Florete OG Jr, Paige GB, Morey TE: Cross sectional and intravascular pressure of the right internal jugular vein during anesthesia: Effects of Trendelenburg position, positive intrathoracic pressure, and hepatic compression. Journal of the Canadian Society of Anesthetists. 1996
5. Banner MJ, Kirby RR, Banner T, Florete OG Jr, et al: Airway pressure release ventilation in patients with acute respiratory failure. Anesthesiology 69:A208, 1989

# REDACTED COPY

6. Layon AJ, Florete OG Jr, Day AL: The effect of duodenojejunal feeding on gastric pH in postoperative ICU patients, abstracted. *Anesthesiology*. 69:A209, 1988

## REFEREED PUBLICATIONS:

1. Lobato EB, Florete O, Bingham HL: A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. *Br J Anaesth* 81:782-784, 1998
2. Lobato EB, Florete OG Jr, Paig, GB, Morey TE: Cross sectional area and intravascular pressure of the right internal jugular vein during anesthesia: effects of Trendelenburg position, positive intrathoracic pressure, and hepatic compression. *J Clin Anesth* 10:1-5, 1998
3. Florete OG Jr: Cancer pain management: A Multidisciplinary Approach. *Jacksonville Medicine*. 46:539, 1995
4. Florete OG Jr, Layon AL: Use of pH paper to reflect gastric pH. *Chest*. 10:886, 1992
5. Layon AJ, Florete OG Jr, Day AL, James PB, McGuigan JE: The effect of duodenojejunal alimentation on gastric pH and hormones in ICU patients. *Chest*. 99:695, 1991
6. Florete OG Jr, Banner MJ, Banner T, Rodriguez J, Kirby RR: Airway pressure release ventilation in a patient with acute lung injury. *Chest*. 96:679, 1989
7. Tangco RR, Florete OG Jr, Abarquez R: Flecainide acetate: Its efficacy and safety in the treatment of ventricular arrhythmias. *Phil J Cardiol*. May, 1986
8. Florete OG Jr, Dantes R: Disseminated Cryptococcoses: A case report. *Phil J Int Med*. 22:1, 1984
9. Ngelangel C, Florete OG Jr, et al: Adrenal cortical carcinoma – rare neoplasm with dramatic clinical manifestations: UPCM-PGH Medical Center experience, 1975-1982. *Phil J Int Med*. 22:2, 1984

## NON-REFEREED PUBLICATIONS:

1. Florete OG Jr: Cardiovascular Physiology. *Osler Institute Anesthesiology Board Review Manual*. 1996
2. Florete OG Jr: Critical Care Medicine. *Osler Institute Anesthesiology Board Review Manual*. 1996
3. Florete OG Jr: Written questions. *Osler Institute Anesthesiology Board Review Manual*. 1996
4. Florete OG Jr: Anesthesia and the Multitrauma Patient. *Manual for the Annual Meeting of the Florida Association of Nurse Anesthetists*. 1996
5. Florete OG Jr: Pain Management. *Osler Institute Anesthesiology Board Review Manual*. Vol 64, 1995
6. Florete OG Jr: Anesthesia for Vascular Surgery. *Osler Institute Board Review Manual*. Vol 64, 1995
7. Florete OG Jr: Autonomics and CNS Drugs. *Osler Institute Anesthesiology Board Review Manual*. Vol 64, 1995
8. Florete OG Jr: Pharmacogenetics. *Osler Institute Anesthesiology Board Review Manual*. Vols. 64 and 66, 1995
9. Florete OG Jr: Intravenous Anesthetics. *Osler Institute Anesthesiology Board Review Manual*. Vol 66, 1995
10. Florete OG Jr: Fluids and Electrolytes. *Osler Institute Anesthesiology Board Review Manual*. Vol 66, 1995

# REDACTED COPY

11. Florete OG Jr: Anesthesia for Coronary Artery Bypass Surgery. Osler Institute Anesthesiology Board Review Manual. Vol 64, 1995
12. Florete OG Jr: Intracranial Hypertension: ICU Assessment and Management. Anesthesia and Critical Care Update. University of Florida. 1988
13. Ramos E, Florete OG Jr, Cabral E: Hypertension – A Monograph. Squibb, Philippines, 1986

## PAPERS, ABSTRACTS, AND LECTURE PRESENTATIONS:

Florete OG Jr: Reevaluating Neuropathic Pain Treatment Algorithms: New Data in the Management of Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Newport News, VA local physicians, June 11, 1999

Florete OG Jr: Reevaluating Neuropathic Pain Treatment Algorithms: New Data in the Management of Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Phillipine Medical Society, Virginia Beach Chapter, Virginia Beach, VA, June 4, 1999

Florete OG Jr: Anesthesiology Board Review Questions. Osler Institute. Philadelphia, PA, May 29, 1999.

Florete OG Jr: Reevaluating Neuropathic Pain Treatment Algorithms: New Data in the Management of Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Jackson, MS local physicians, May 21, 1999

Florete OG Jr: Diagnosis and Treatment of Migraine Headaches, Northeast Society of Hospital Pharmacies meeting, Jacksonville Hilton, Jacksonville, Florida, May 13, 1999

Florete OG Jr: Reevaluating Neuropathic Pain Treatment Algorithms: New Data in the Management of Diabetic Peripheral Neuropathy and Postherpetic Neuralgia” Health Seminar Management Consultants, Orlando, Florida, April 24, 1999

Florete OG Jr: Reevaluating Neuropathic Pain Treatment Algorithms: New Data in the Management of Diabetic Peripheral Neuropathy and Postherpetic Neuralgia” Local Lakeland Physicians, Lakeland, Florida, April 21, 1999

Florete OG Jr: Management of Migraine, sponsored by Glaxo Wellcome Dr. Victor Micolucci’s office, Jacksonville, Florida, April 29, 1999

Florete OG Jr: Reevaluating Neuropathic Pain Treatment Algorithms: New Data in the Management of Diabetic Peripheral Neuropathy and Postherpetic Neuralgia” Phillipine Medical Society, Tampa Chapter, Tampa, Florida, February 27, 1999

Florete OG Jr: Parke-Davis Advisory Board Meeting “Evolving Role of Anticonvulsants: New Treatments, New Strategies” Curacao, Netherland Antilles. January 14-16, 1999

Florete OG Jr: The Purdue Frederick Company Physicians’ Pain Management Speakers Training Program, Hyatt Regency San Antonio on the Riverwalk, San Antonio, Texas, October 9-11, 1998

Florete OG Jr: Acute Pain Management - Emergency Medicine Update – Thomas M. Bozzuto, D.O., Baptist Medical Center, Jacksonville, Florida, October 21, 22, 1998

Florete OG Jr: Lecture, St. Augustine Fibromyalgia Support Group, St. Augustine Florida, October 17, 1998

Florete OG Jr: Cancer Pain Management: The Role of Anti-Convulsants. The Northern Region of the Florida Cancer Pain Initiative Meeting. Jacksonville, Florida, June 18, 1998

Florete OG Jr: Anesthesiology Questions Review Course. Osler Institute. Dallas, Texas, June 11, 1998.

# REDACTED COPY

Florete OG Jr: Pain Management: An Interdisciplinary Approach. Lecture for local physicians in Jacksonville. University Club, Jacksonville, Florida, May 28, 1998

Florete OG Jr: Speaker, Jacksonville Area Reflex Sympathetic Dystrophy & Chronic Pain Support Group, Jacksonville Beach, Florida, May 27, 1998

Florete OG Jr: Interventional Algology. The Indian Medical Society Annual Meeting, Jacksonville Florida, April 24, 1998

Florete OG Jr: Cryoablation Hands-on Cadaver workshop. Uniformed Services University of the Health Sciences, Bethesda, Maryland, March 28-29, 1998

Florete OG Jr: First National Cryoablation Cadaver Workshop. Southeastern Seminars, Inc., Orlando, Florida, October 1997.

Florete OG Jr: Mylotec – Epiduroscopy, Questions and Answers Spinal Cord Stimulators for Northeast Florida State Association of Rehabilitation Nurses, Genesis Rehabilitation, Jacksonville, Florida, September 8, 1997

Florete OG Jr: Update on Analgesia and Sedation in the ICU, Quarterly Critical Care Meeting. Memorial Hospital West Volusia, Deland, Florida, April 30, 1997

Florete OG Jr: Migraine Headache. Wellness Council of North Florida Annual Meeting, Jacksonville, Florida, March 28, 1997.

Florete OG Jr: Mock Oral Board Examination. Osler Institute Anesthesiology Review Course, Atlanta, Georgia, March 23-25, 1996.

Florete OG Jr: Pain Management: A Multidisciplinary Approach. United States Department of Labor Medical Training for Claims Examiners, Jacksonville, Florida, February 27, 1996.

Florete OG Jr: Anesthesia and the Multitrauma Patient, lectured at the Florida Association of Nurse Anesthetists' Annual Meeting, Ocala, Florida, February 17, 1996.

Florete OG Jr: Pharmacogenetics, lectured at the Osler Institute Anesthesiology Review Course #72, Dallas, Texas, February 15, 1996.

Florete OG Jr: Critical Care, lectured at the Osler Institute Anesthesiology Review Course #72, Dallas, Texas, February 15, 1996.

Florete OG Jr: Autonomics and CNS Drugs, lectured at the Osler Institute Anesthesiology Review Course #72, Dallas, Texas, February 15, 1996.

Florete OG Jr: Fluids and Electrolytes, lectured at the Osler Institute Anesthesiology Review Course #72, Dallas, Texas, February 14, 1996.

Florete OG Jr: Cardiac Physiology, lectured at the Osler Institute Anesthesiology Review Course #72, Dallas, Texas, February 14, 1996.

Florete OG Jr: Written Questions, lectured at the Osler Institute Anesthesiology Review Course #72, Dallas, Texas, February 14, 1996.

Florete OG Jr: Mock Oral Board Examination, lectured at the Osler Institute Anesthesiology Review Course #72, Dallas, Texas, February 14-16, 1996.

# REDACTED COPY

Florete OG Jr: Cancer Pain Management, lectured at the Baptist Medical Center Nurses Training Seminar, Jacksonville, Florida, February 9, 1996.

Florete OG Jr: Intravenous Anesthesia, lectured at the Anesthesiology Oral Board Tutorial. Osler Institute. Fort Lauderdale, Florida, October 4, 1995.

Florete OG Jr: Pain Management, lectured at the Anesthesiology Oral Board Tutorial. Osler Institute. Fort Lauderdale, Florida, October 4, 1995.

Florete OG Jr: Autonomic and CNS Drugs, lectured at the Anesthesiology Oral Board tutorial. Osler Institute. Fort Lauderdale, Florida, October 4, 1995.

Florete OG Jr: Pharmacogenetics, lectured at the Anesthesiology Oral Board tutorial. Osler Institute. Fort Lauderdale, Florida, October 4, 1995.

Florete OG Jr: Intravenous Anesthetics, lectured at the Osler Institute Anesthesiology Review Course #70, Fort Lauderdale, Florida, October 4, 1995.

Florete OG Jr: Anesthesiology Oral Board Tutorial. Mock Oral Examiner. Osler Institute. Fort Lauderdale, Florida, October 3-8. 1995.

Florete OG Jr: Autonomics and CNS Drugs, Lectured at the Osler Institute Anesthesiology Review Course #70. Fort Lauderdale, Florida, October 3, 1995.

Florete OG Jr: Anesthesiology Mock Oral Examination. Osler Institute Anesthesiology Review Course #70, Fort Lauderdale, Florida, October 1-7, 1995.

Florete OG Jr: Anesthesiology Mock Oral Examination. Osler Institute Anesthesiology Review course #67, Atlanta, Georgia, September 2-4, 1995.

Florete OG Jr: Pharmacogenetics, lectured at the Osler Institute's Anesthesiology Board Review Course #66, Tampa, Florida, August 5, 1995

Florete OG Jr: Intravenous Anesthesia, lectured at the Osler Institute's Anesthesiology Board Review Course #66, Tampa, Florida, August 5, 1995

Florete OG Jr: Fluids and Electrolytes, lectured at the Osler Institute's Anesthesiology Board Review Course #66, Tampa, Florida, August 5, 1995

Florete OG Jr: Pain Management. Medical Grand rounds. University of Florida Health Science Center Jacksonville, August 2, 1995

Florete OG Jr: Anesthesia for Vascular Surgery, lectured at the Osler Institute's Anesthesiology Board Review Course #64, Chicago, July 5, 1995.

Florete OG Jr: Anesthesia for coronary Artery Bypass Surgery, lectured at the Osler Institute's Anesthesiology Board Review Course #64, Chicago, July 5, 1995.

Florete OG Jr: Pharmacogenetics, lectured at the Osler Institute's Anesthesiology Board Review Course #64, Chicago, July 5, 1995.

Florete OG Jr: Anesthesiology Mock Oral Examination. Osler Institute Anesthesiology Board Review Course #64, Chicago, July 4-5 1995

Florete OG Jr: Pharmacogenetics, lectured at the Osler Institute's Anesthesiology Board Review Course #64, Chicago, July 4, 1995.

# REDACTED COPY

Florete, OG Jr, Branc MN, Sanchez M, Desautels DA, Gallagher TJ: Hyperbaric oxygen therapy in carbon monoxide poisoning, presented in the 17<sup>th</sup> Annual gulf-Atlantic Anesthesia Residents' Conference, University of Kentucky, Lexington, Kentucky. April 1991.

Dibenedetto RJ, Florete OG Jr, Kirby RR, Banner T, Gravenstein N: Weaning from mechanical ventilation – arterial blood gas analysis compared with oximetry/capnography, presented in the 17<sup>th</sup> Annual Gulf-Atlantic Anesthesia Residents' conference, University of Kentucky, Lexington, Kentucky. April, 1991.

Hennig JL, Florete OG Jr, Desautels DA, Gallagher TJ: Treatment of air embolism: The role of hyperbaric oxygen therapy, presented in the 17<sup>th</sup> Annual gulf-Atlantic Anesthesia Residents' Conference, University of Kentucky, Lexington, Kentucky. April, 1991.

Florete OG Jr, Layon AJ, Day AL, James PA, Mcguigan JE: Gastric pH and hormones during duodenojejunal feeding in ICU patients, presented in the 15<sup>th</sup> Annual Gulf-Atlantic Anesthesia Residents' conference, Tulane University, New Orleans, Louisiana. April, 1989.

Florete OG Jr: Hyperbaric Oxygen: Uses and Clinical Application. Emergency Medical Technicians Meeting, Daytona Beach, Florida. December 3-5, 1988.

Florete OG Jr: Intracranial hypertension: ICU assessment and management. Anesthesiology and Critical Care update: symposium for Physicians, nurses and respiratory therapists. Lake Buena Vista, Florida. November 19-23, 1988

Florete OG Jr, Layon AJ, et al: The effect of duodenojejunal feeding on gastric pH in postoperative ICU patients, poster presentation, 1988 Annual Meeting, American Society of Anesthesiologists, San Francisco, California, October 8-12, 1988.

Florete OG Jr, Banner MJ, Banner CE, Rodriguez J. Kirby RR: Airway pressure release ventilation: A new mode of ventilation, presented in the 14<sup>th</sup> Annual Gulf-Atlantic Anesthesia Residents' Conference. Medical College of Georgia, Augusta, Georgia, May, 1988.

Seitz PA, Florete OG Jr, Gravenstein N: Endobronchial rupture from endotracheal reintubation with a tube guide, presented in the 14<sup>th</sup> annual Gulf Anesthesia Residents' Conference. Medical College of Georgia, Augusta, Georgia, May 1988.

.

# REDACTED COPY

## Richard Tempel, MD, FACEP

16230 Vetta Drive  
Montverde, FL 34756  
407-756-3717  
drtempel@gmail.com

### **EDUCATION**

2003 – 2006 Duke University Emergency Medicine Residency Program, Chief Resident  
1999 – 2003 University of Maryland School of Medicine, Medical Doctorate  
1996 – 1999 University of Maryland College Park, BS, General Biology

### **EMERGENCY MEDICINE**

May 2018 - Present	Emergency Physicians of Central Florida, Orlando Health
November 2008 – May 2018	Florida Emergency Physicians, Florida Hospital
August 2006 – November 2008	Maryland Emergency Medicine Network, Bel Air, MD
May 2006 - November 2008	Saint Joseph Medical Center, Towson, Maryland

### **MEDICAL CANNABIS EXPERIENCE**

2015-2018	Medical Director, CHT / Liberty Health Sciences
2018-2019	Medical Cannabis Clinic Director, Aurelian Medical
2019-Present	Medical Director, Green Growth Brands/ Jungle Boys

### **ADDITIONAL EMPLOYMENT AND AFFILIATIONS**

Medical Director, Blue Cedar Freestanding Emergency Department (2021-Present)  
University of Central Florida (UCF), College of Medicine, Assistant Professor  
Preceptor, Nova Southeast University Family Medicine Residency (2012-2018)  
Medical Director, Orlando Resorts Medispa (2013-2016)

### **LICENSURE AND CERTIFICATIONS**

American Board of Emergency Medicine (ABEM), June 2007-present  
State of Florida Medical Licensure (License ME102329) 2008 - present  
AMET certified for Botox and Dermal Fillers 2013- present  
Medical Director Certification for MMTCs, FMA - 2016 - present  
Hazard Analysis and Critical Control Points (HACCP) Certification, NC State, 2020

# REDACTED COPY

## **PROFESSIONAL ORGANIZATIONS**

Fellow, American College of Emergency Physicians (ACEP)  
Florida Medical Association (FMA)

## **AWARDS AND HONORS**

Chief Resident, Division of Emergency Medicine, Duke University Medical Center  
Graduating Resident of the Year 2006, Duke University Medical Center

## **PUBLICATIONS/MEDIA**

2019	<i>Is Vaping Deadly?</i> Podcast, Learn Sativa College
2018	Weediatics: A Covert Medical Mission. Documentary. 2020 Green Bay Film Festival Best Documentary Award.
2006	<i>Infectious Disease in a disaster zone.</i> <u>Disaster Medicine</u> . Ciottone editor. Section 4, Chapter 46. Mosby. March 2006. ISBN:0323032532
2006	Proposing short-term observation for the disposition of patients with decompression illness; UHMS, Vol 35, No 2, June 2006.



**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**









**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**




**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.9.5 – Medical Director Acknowledgment  
and Certificate of Course Completion**





**FORM 4: MEDICAL DIRECTOR ACKNOWLEDGMENT**

I, Orlando Florete Sr., have consented to be employed as the medical director for Connaissance Software LLC, an applicant for MMTC licensure pursuant to section 381.986, F.S. I have successfully completed the 2-hour course and examination for medical directors offered by the Florida Medical Association or Florida Osteopathic Medical Association concerning the requirements of section 381.986, F.S. I understand and agree that, upon licensure by the Department, I am responsible for supervising the activities of the MMTC. I understand that if I knowingly make a false statement in writing with the intent to mislead a public servant in the performance of his or her official duty, that I may be found guilty of a misdemeanor of the second degree, punishable as provided in sections 775.082 or 775.083, F.S.

Name (Printed):

Orlando Florete Sr.

Signature:

[Signature]

Florida MD or DO License #:

HE0058430



## Florida Medical Association

Certifies that

Orlando Garay Florete

*has participated in the enduring material titled*

## Florida Medical Marijuana Course for MMTC Medical Directors


on 4/17/2023 10:22 PM Eastern

*and is awarded 2.00 AMA PRA Category 1 Credits™ (Enduring Material)*

The Florida Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Florida Medical Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™ (Enduring Material)

Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**FORM 4: MEDICAL DIRECTOR ACKNOWLEDGMENT**

I, Richard Tempel, MD, have consented to be employed as the medical director for \_\_\_\_\_, an applicant for MMTC licensure pursuant to section 381.986, F.S. I have successfully completed the 2-hour course and examination for medical directors offered by the Florida Medical Association or Florida Osteopathic Medical Association concerning the requirements of section 381.986, F.S. I understand and agree that, upon licensure by the Department, I am responsible for supervising the activities of the MMTC. I understand that if I knowingly make a false statement in writing with the intent to mislead a public servant in the performance of his or her official duty, that I may be found guilty of a misdemeanor of the second degree, punishable as provided in sections 775.082 or 775.083, F.S.

Name (Printed):

Richard A. Tempel, MD

Signature:

[Signature]

Florida MD or DO License #:

ME102329

**REDACTED COPY**

## Florida Medical Association

Certifies that

Richard Andrew Tempel

*has participated in the enduring material titled*

### **Florida Medical Marijuana Course for MMTC Medical Directors**

on 3/1/2022 6:50 PM Eastern

*and is awarded 2.00 AMA PRA Category 1 Credits™ (Enduring Material)*

The Florida Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Florida Medical Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™ (Enduring Material)

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**























**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**





**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**





**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**











**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**





**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**REDACTED COPY**

**CONNAISSANCE SOFTWARE, LLC**

Financial Statements  
And  
Independent Auditor's Report

December 31, 2022





















**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**









**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**











































**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

**Subsection 4.12.3 – Projected Budget**











**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

















**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

Not Applicable to Applicant.

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

















































**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**
























**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**


**Application for MMTC Licensure**



## FORM 3(A): ENTITY APPLICANT ACKNOWLEDGMENT AND STATEMENT OF UNDERSTANDING

I, Bruce Knox, the undersigned representative, hereby represent and warrant that I am authorized to submit this application on behalf of the entity listed on the application (the Applicant) and to attest to the following on behalf of the Applicant.

- All information included in the application is true and correct. Applicant understands that the Department will rely on such information, and that any material misrepresentation in this application is grounds for licensure denial. Further, Applicant understands that if the applicant knowingly makes a false statement in writing with the intent to mislead a public servant in the performance of his or her official duty, the applicant may be found guilty of a misdemeanor of the second degree, punishable as provided in sections 775.082 or 775.083, F.S.
- Applicant understands that this application for licensure creates neither an entitlement to, nor a vested right in, licensure.
- No individual or entity that owns, controls, or holds power to vote 5 percent or more of the voting shares of the Applicant has any direct or indirect ownership or control of a voting share of any currently licensed MMTC.
- No individual or entity that owns, controls, or holds power to vote 5 percent or more of the voting shares of any currently licensed MMTC has any direct or indirect ownership or control of a voting share of the Applicant.
- No currently licensed MMTC has any direct or indirect ownership or control of any voting shares or other form of ownership of the Applicant.
- The Applicant does not have any direct or indirect ownership or control of any voting shares or other form of ownership of a currently licensed MMTC.



- Notwithstanding the contents of the application, upon licensure, Applicant agrees to abide by, and be bound to, all the requirements of section 381.986, F.S., and all Department rules relating to medical marijuana and medical marijuana treatment centers.
- Applicant understands and agrees that if the Department determines at any point after licensure that the application contained a material misrepresentation, then the license will be revoked.

Representative Name (Printed): Bruce Knox

Representative Signature: 

MMTC Applicant Name: Connaissance Software LLC

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

Not Applicable to Applicant.

**REDACTED COPY**

**Connaissance Software, LLC  
dba Trust Wellness**

**Application for MMTC Licensure**

Not Applicable to Applicant.

**Section 4.16 - Pigford/BFL Application Fee Transfer Request**